Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

Human Molecular Genetics

Volumn 23, Issue 14, 2014, Pages 3716-3732

  Stack, Cliona ^a   Jainuddin, Shari ^a   Elipenahli, Ceyhan ^a   Gerges, Meri ^a   Starkova, Natalia ^a   Starkov, Anatoly A ^a   Jové, Mariona ^b   Portero Otin, Manuel ^b   Launay, Nathalie ^c,d   Pujol, Aurora ^c,d,e   Kaidery, Navneet Ammal ^f   Thomas, Bobby ^f   Tampellini, Davide ^g   Flint Beal, M ^a   Dumont, Magali ^a,h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF LLEIDA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g INSERM   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; METHYLENE BLUE; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; ASTROCYTOSIS; BEHAVIOR; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIET; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GENE ACTIVATION; GENE EXPRESSION; INFLAMMATION; LOW DRUG DOSE; MALE; MEDIATOR; MITOCHONDRION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; TAUOPATHY; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TAUOPATHIES; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; METHYLENE BLUE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SEX FACTORS; SIGNAL TRANSDUCTION; TAU PROTEINS; TAUOPATHIES;

EID: 84902953435     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu080     Document Type: Article

References (87)

1. Walker, L.C., Diamond, M.I., Duff, K.E. and Hyman, B.T. (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol., 70, 304-310.
2. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Ghanbari, H., Wataya, T., Shimohama,S. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 60, 759-767.
3. Sultana, R. and Butterfield, D.A. (2009) Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr., 41, 441-446.
4. Sultana, R., Perluigi, M. and Butterfield, D.A. (2009) Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol., 118, 131-150.
5. Coppede, F. and Migliore, L. (2009)DNAdamage and repair in Alzheimer's disease. Curr. Alzheimer Res., 6, 36-47.
6. Markesbery, W.R., Kryscio, R.J., Lovell, M.A. and Morrow, J.D. (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol., 58, 730-735.
7. Williams, T.I., Lynn, B.C., Markesbery, W.R. and Lovell, M.A. (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging, 27, 1094-1099.
8. Perry, V.H., Nicoll, J.A. and Holmes, C. (2010) Microglia in neurodegenerative disease. Nat. Rev. Neurol., 6, 193-201.
9. Wyss-Coray, T. and Rogers, J. (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med., 2, a006346.
10. Prasad, S., Sung, B. and Aggarwal, B.B. (2012) Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev. Med., 54(suppl), S29-S37.
11. Rojas, J.C., Bruchey, A.K. and Gonzalez-Lima, F. (2012) Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol., 96, 32-45.
12. Walter-Sack, I., Rengelshausen, J., Oberwittler, H., Burhenne, J., Mueller, O., Meissner, P. and Mikus, G. (2009) High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur. J. Clin. Pharmacol., 65, 179-189.
13. Schirmer, R.H., Adler, H., Pickhardt,M.and Mandelkow, E. (2011) 'Lestwe forget you-methylene blue. . .'. Neurobiol. Aging, 32, 2325 e7-2325 e16.
14. Fatouros, C., Pir, G.J., Biernat, J., Koushika, S.P., Mandelkow, E., Mandelkow, E.M., Schmidt, E. and Baumeister, R. (2012) Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet., 21, 3587-3603.
15. Wischik, C.M., Edwards, P.C., Lai, R.Y., Roth, M. and Harrington, C.R. (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA, 93, 11213-11128.
16. Akoury, E., Pickhardt, M., Gajda, M., Biernat, J., Mandelkow, E. and Zweckstetter, M. (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew. Chem. Int. Ed. Engl., 52, 3511-3515.
17. Crowe, A., James, M.J., Lee, V.M., Smith, A.B. 3rd, Trojanowski, J.Q., Ballatore, C. and Brunden, K.R. (2013) Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J. Biol. Chem., 288, 11024-11037.
18. Congdon, E.E.,Wu,J.W., Myeku,N., Figueroa, Y.H., Herman, M., Marinec, P.S., Gestwicki, J.E., Dickey, C.A., Yu, W.H. and Duff, K.E. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy, 8, 609-622.
19. Landhuis, E. (2012) Will tau drug show its true colors in phase 3 trials? Alzforum.
20. Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N.N., Yang, L., Starkov, A.A. and Beal, F. (2011) Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J., 25, 4063-4072.
21. Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T. et al. (2011) P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE, 6, e21050.
22. Beal, M.F. (2004) Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr., 36, 381-386.
23. Romano, A.D., Serviddio, G., de Matthaeis, A., Bellanti, F. and Vendemiale, G. (2010) Oxidative stress and aging. J. Nephrol., 23(Suppl. 15), S29-S36.
24. Kumar, R. and Atamna, H. (2011) Therapeutic approaches to delay the onset of Alzheimer's disease. J. Aging Res., 2011, 820903.
25. D'Aurelio, M., Vives-Bauza, C., Davidson, M.M. and Manfredi, G. (2010) MitochondrialDNAbackground modifies the bioenergetics ofNARP/MILS ATP6 mutant cells. Hum. Mol. Genet., 19, 374-386.
26. Markesbery, W.R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med., 23, 134-147.
27. Castellani, R., Smith, M.A., Richey, P.L., Kalaria, R., Gambetti, P. and Perry, G. (1995) Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res., 696, 268-271.
28. Schipper, H.M. (2004) Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med., 37, 1995-2011.
29. Hartzler, A.W., Zhu, X., Siedlak, S.L., Castellani, R.J., Avila, J., Perry, G. and Smith, M.A. (2002) The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol. Aging, 23, 855-859.
30. Wyss-Coray, T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med., 12, 1005-1015.
31. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q. and Lee, V.M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron, 53, 337-351.
32. Bruchey, A.K. and Gonzalez-Lima, F. (2008) Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue. Am. J. Pharmacol. Toxicol., 3, 72-79.
33. Riha, P.D., Bruchey, A.K., Echevarria, D.J. and Gonzalez-Lima, F. (2005) Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur. J. Pharmacol., 511, 151-158.
34. van Bebber, F., Paquet, D., Hruscha, A., Schmid, B. and Haass, C. (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol. Dis., 39, 265-271.
35. O'Leary, J.C. 3rd, Li, Q., Marinec, P., Blair, L.J., Congdon, E.E., Johnson, A.G., Jinwal, U.K., Koren, J. 3rd, Jones, J.R., Kraft, C. et al. (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener., 5, 45.
36. Medina, D.X., Caccamo, A. and Oddo, S. (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol., 21, 140-149.
37. Hosokawa, M., Arai, T., Masuda-Suzukake, M., Nonaka, T., Yamashita, M., Akiyama, H. and Hasegawa, M. (2012) Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS ONE, 7, e52389.
38. Ikeda, M., Shoji, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., Sasaki, A., Tomidokoro, Y., Ikarashi, Y., Kuribara, H. et al. (2005) Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am. J. Pathol., 166, 521-531.
39. Messing, L., Decker, J.M., Joseph, M., Mandelkow, E. and Mandelkow, E.M. (2013) Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol. Aging, 34, 1343-1354.
40. Howells, C., Saar, K., Eaton, E., Ray, S., Palumaa, P., Shabala, L., Adlard, P.A., Bennett, W., West, A.K., Guillemin, G.J. et al. (2012) Redox-active Cu(II)-Abeta causes substantial changes in axonal integrity in cultured cortical neurons in an oxidative-stress dependent manner. Exp. Neurol., 237, 499-506.
41. Calabrese, V., Guagliano, E., Sapienza, M., Panebianco, M., Calafato, S., Puleo, E., Pennisi, G., Mancuso, C., Butterfield, D.A. and Stella, A.G. (2007) Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem. Res., 32, 757-773.
42. Patenaude, A., Murthy, M.R. and Mirault, M.E. (2005) Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol. Life Sci., 62, 1063-1080.
43. Kalinina, E.V., Chernov, N.N. and Saprin, A.N. (2008) Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc), 73, 1493-1510.
44. Power, J.H., Asad, S., Chataway, T.K., Chegini, F., Manavis, J., Temlett, J.A., Jensen, P.H., Blumbergs, P.C. and Gai, W.P. (2008) Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol., 115, 611-622.
45. Lillig, C.H., Berndt, C. and Holmgren, A. (2008) Glutaredoxin systems. Biochim. Biophys. Acta, 1780, 1304-1317.
46. Yoshida, T., Nakamura, H., Masutani, H. and Yodoi, J. (2005) The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann. N Y Acad. Sci., 1055, 1-12.
47. Godoy, J.R., Oesteritz, S., Hanschmann, E.M., Ockenga, W., Ackermann, W. and Lillig, C.H. (2011) Segment-specific overexpression of redoxins after renal ischemia and reperfusion: protective roles of glutaredoxin 2, peroxiredoxin 3, and peroxiredoxin 6. Free Radic. Biol. Med., 51, 552-561.
48. Akterin, S., Cowburn, R.F., Miranda-Vizuete, A., Jimenez, A., Bogdanovic, N., Winblad, B. and Cedazo-Minguez, A. (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ., 13, 1454-1465.
49. Yata, K., Oikawa, S., Sasaki, R., Shindo, A., Yang, R., Murata, M., Kanamaru,K. and Tomimoto, H. (2011) Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse. Brain Res., 1410, 12-23.
50. Landino, L.M., Skreslet, T.E. and Alston, J.A. (2004) Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J. Biol. Chem., 279, 35101-35105.
51. Prasad, K.N., Cole, W.C. and Prasad, K.C. (2002) Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J. Am. Coll. Nutr., 21, 506-522.
52. David, D.C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., Ravid, R., Drose, S., Brandt, U., Muller, W.E. et al. (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem., 280, 23802-23814.
53. Melov, S., Adlard, P.A., Morten, K., Johnson, F., Golden, T.R., Hinerfeld, D., Schilling, B., Mavros, C., Masters, C.L., Volitakis, I. et al. (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE, 2, e536.
54. Schulz, K.L., Eckert, A., Rhein, V., Mai, S., Haase, W., Reichert, A.S., Jendrach, M., Muller, W.E. and Leuner, K. (2012) A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol., 46, 205-216.
55. DuBoff, B., Gotz, J. and Feany, M.B. (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron, 75, 618-632.
56. Atamna, H. and Kumar, R. (2010) Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J. Alzheimers Dis., 20(Suppl. 2), S439-S452.
57. Lin, A.L., Poteet, E., Du, F., Gourav, R.C., Liu, R., Wen, Y., Bresnen, A., Huang, S., Fox, P.T., Yang, S.H. et al. (2012) Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS ONE, 7, e46585.
58. Wrubel, K.M., Riha, P.D., Maldonado, M.A., McCollum, D. and Gonzalez-Lima, F. (2007) The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol. Biochem. Behav., 86, 712-717.
59. Murakami, K., Murata, N., Noda, Y., Tahara, S., Kaneko, T., Kinoshita, N., Hatsuta, H., Murayama, S., Barnham, K.J., Irie, K. et al. (2011) SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J. Biol. Chem., 286, 44557-44568.
60. Dumont, M., Wille, E., Stack, C., Calingasan, N.Y., Beal, M.F. and Lin, M.T. (2009) Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J., 23, 2459-2466.
61. Miyata, Y., Rauch, J.N., Jinwal, U.K., Thompson, A.D., Srinivasan, S., Dickey, C.A. and Gestwicki, J.E. (2012) Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem. Biol., 19, 1391-1399.
62. Jinwal, U.K., Miyata, Y., Koren, J. 3rd, Jones, J.R., Trotter, J.H., Chang, L., O'Leary, J., Morgan, D., Lee, D.C., Shults, C.L. et al. (2009) Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci., 29, 12079-12088.
63. Hybertson, B.M., Gao, B., Bose, S.K. and McCord, J.M. (2011) Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Aspects Med., 32, 234-246.
64. Lu,S.C. (2009) Regulation of glutathione synthesis. Mol.AspectsMed.,30,42-59.
65. Tanito, M., Agbaga, M.P. and Anderson, R.E. (2007) Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. Free Radic. Biol. Med., 42, 1838-1850.
66. Korolainen, M.A., Auriola, S., Nyman, T.A., Alafuzoff, I. and Pirttila, T. (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol. Dis., 20, 858-870.
67. Johnson, J.A., Johnson,D.A.,Kraft,A.D., Calkins, M.J., Jakel,R.J.,Vargas,M.R. and Chen, P.C. (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann. N Y Acad. Sci., 1147, 61-69.
68. Maher, P. (2006) Redox control of neural function: background, mechanisms, and significance. Antioxid. Redox. Signal, 8, 1941-1970.
69. Kim, Y.C., Yamaguchi, Y., Kondo, N., Masutani, H. and Yodoi, J. (2003) Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene, 22, 1860-1865.
70. Ma, Q.L., Zuo, X., Yang, F., Ubeda, O.J., Gant, D.J., Alaverdyan, M., Teng, E., Hu, S., Chen, P.P., Maiti, P. et al. (2013) Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J. Biol. Chem., 288, 4056-4065.
71. Pickering, A.M., Linder, R.A., Zhang, H., Forman, H.J. and Davies, K.J. (2012) Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. J. Biol. Chem., 287, 10021-10031.
72. Yang, C., Zhang, X., Fan, H. and Liu, Y. (2009) Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res., 1282, 133-141.
73. Kanninen, K., Heikkinen, R., Malm, T., Rolova, T., Kuhmonen, S., Leinonen, H., Yla-Herttuala, S., Tanila, H., Levonen, A.L., Koistinaho, M. et al. (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA, 106, 16505-16510.
74. Dumont, M., Wille, E., Calingasan, N.Y., Tampellini, D., Williams, C., Gouras, G.K., Liby, K., Sporn, M., Nathan, C., Flint Beal, M. et al. (2009) Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J. Neurochem., 109, 502-512.
75. Stack, C., Ho, D., Wille, E., Calingasan, N.Y., Williams, C., Liby, K., Sporn, M., Dumont, M. and Beal, M.F. (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic. Biol. Med., 49, 147-158.
76. Neymotin, A., Calingasan, N.Y., Wille, E., Naseri, N., Petri, S., Damiano, M., Liby, K.T., Risingsong, R., Sporn, M., Beal, M.F. et al. (2011) Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med., 51, 88-96.
77. Yang, L., Calingasan, N.Y., Thomas, B., Chaturvedi, R.K., Kiaei, M., Wille, E.J., Liby, K.T., Williams, C., Royce, D., Risingsong, R. et al. (2009) Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE, 4, e5757.
78. Kaidery, N.A., Banerjee, R., Yang, L., Smirnova, N.A., Hushpulian, D.M., Liby, K.T., Williams, C.R., Yamamoto, M., Kensler, T.W., Ratan, R.R. et al. (2013) Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid. Redox. Signal., 18, 139-157.
79. McCord, J.M. and Fridovich, I. (1970) The utility of superoxide dismutase in studying free radical reactions. II.Themechanismof the mediationof cytochrome c reduction by a variety of electron carriers. J. Biol. Chem., 245, 1374-1377.
80. Kelner, M.J., Bagnell, R., Hale, B. and Alexander, N.M. (1988) Methylene blue competes with paraquat for reduction by flavo-enzymes resulting in decreased superoxide production in the presence of heme proteins. Arch. Biochem. Biophys., 262, 422-426.
81. Salaris, S.C., Babbs, C.F. and Voorhees, W.D. 3rd. (1991) Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for the attenuation of ischemia/reperfusion injury. Biochem. Pharmacol., 42, 499-506.
82. Mayer, B., Brunner, F. and Schmidt, K. (1993) Inhibition of nitric oxide synthesis by methylene blue. Biochem. Pharmacol., 45, 367-374.
83. Kelner, M.J. and Alexander, N.M. (1985) Methylene blue directly oxidizes glutathione without the intermediate formation of hydrogen peroxide. J. Biol. Chem., 260, 15168-15171.
84. Bongard, R.D.,Merker, M.P., Shundo, R., Okamoto, Y., Roerig, D.L., Linehan, J.H. and Dawson, C.A. (1995) Reduction of thiazine dyes by bovine pulmonary arterial endothelial cells in culture.Am. J. Physiol., 269,L78-L84.
85. May, J.M., Qu, Z.C. and Cobb, C.E. (2004) Reduction and uptake of methylene blue by human erythrocytes. Am. J. Physiol. Cell Physiol., 286, C1390-C1398.
86. Dumont, M., Wille, E., Calingasan, N.Y., Nathan, C., Flint Beal, M. and Lin, M.T. (2010) N-iminoethyl-L-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition. Neurochem. Int., 56, 345-351.
87. Galino, J., Ruiz, M., Fourcade, S., Schluter, A., Lopez-Erauskin, J., Guilera, C., Jove, M., Naudi, A., Garcia-Arumi, E., Andreu, A.L. et al. (2011) Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid. Redox. Signal, 15, 2095-2107.